Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Neovacs    ALNEV   FR0004032746

NEOVACS (ALNEV)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
0.93(c) 0.94(c) 0.93(c) 0.93(c) 0.9(c) Last
334 411 278 734 146 865 264 488 369 922 Volume
+1.09% +1.08% -1.06% 0.00% -3.23% Change
More quotes
Financials (€)
Sales 2016 0,60 M
EBIT 2016 -12,8 M
Net income 2016 -10,9 M
Debt 2016 1,47 M
Yield 2016 -
Sales 2017 5,51 M
EBIT 2017 -10,8 M
Net income 2017 -11,1 M
Debt 2017 10,0 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 66,6x
EV / Sales2017 8,85x
Capitalization 38,7 M
More Financials
Company
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory and cancerous diseases.It focuses on the development of Tumor Necrosis Factor-Kinoid for treating Crohn's disease and rheumatoid polyarthritis and... 
More about the company
Surperformance© ratings of Neovacs
Trading Rating : Investor Rating :
More Ratings
Latest news on NEOVACS
03/23 ORIGINAL-RESEARCH : Neovacs S.A. (von GBC AG): BUY
03/13NEOVACS SA : annual earnings release
03/10 NEOVACS : to present IFNalpha Kinoid technology and its clinical outlooks at upc..
03/09 Neovacs to Present IFNα Kinoid Technology and Its Clinical Outlooks at ..
03/09 NEOVACS : to present IFNalpha Kinoid technology and its clinical outlooks at upc..
02/22 NEOVACS : and BioSense Sign Option Agreement Worth Up to 65 Million Plus Royalti..
02/21 NEOVACS : AND BIOSENSE SIGN OPTION AGREEMENT WORTH UP TO €65 MILLION PLUS ROYALT..
02/21 NEOVACS : AND BIOSENSE SIGN OPTION AGREEMENT WORTH UP TO €65 MILLION PLUS ROYALT..
02/16 NEOVACS : Stellar Biotechnologies Congratulates Partner's Decision to Extend Dru..
02/10 NEOVACS : Issued New Broad Patent in China for IFN Kinoid
More news
Sector news : Biotechnology & Medical Research - NEC
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
03/23Original-Research: Neovacs S.A. (von GBC AG): BUY  
03/09Neovacs to Present IFNα Kinoid Technology and Its Clinical Outlooks.. 
03/09Neovacs : to present IFNalpha Kinoid technology and its clinical outlooks at .. 
02/26#EquityResearch Week In Review: BioSense Signs $68 Million China Deal With Ne.. 
02/26Week In Review: BioSense Signs $68 Million China Deal With Neovacs For Therap.. 
More tweets
Qtime:10
Advertisement
Chart NEOVACS
Duration : Period :
Neovacs Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 2,37 €
Spread / Average Target 163%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miguel Sieler Chief Executive Officer & Director
Jean-Jacques Bertrand Chairman
Baptiste Pourtout Head-Finance
Géraldine Grouard-Vogel Chief Scientific Officer
Thérèse Croughs Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NEOVACS11.11%42
INCYTE CORPORATION39.26%28 461
QUINTILES IMS HOLDINGS..2.55%18 400
LONZA GROUP AG3.40%10 646
CELLTRION, INC.--.--%9 851
SEATTLE GENETICS, INC.20.69%9 075
More Results